Dublin-listed pharma services company Open Orphan has had the results of a clinical trial published in one of the world’s oldest and best known medical journals, The Lancet. The first trial of AGS-v, a first-in-class "mosquito saliva vaccine" in humans indicated that the vaccine is safe and induces a strong immune response in healthy volunteers. These positive findings suggest that AGS-v is now ready to advance to Phase II, a statement from Open Orphan, which owns a 49pc stake of Imutex – the company developing the treatment – said. In the study published in The Lancet, NIAID scientists describe the results of the Phase 1 trial of the vaccine as "encouraging and worthy of further study". Cathal Friel, chairman of Open Orphan, said: "We are delighted with the results of this very important and successful trial of Imutex's universal vaccine for mosquito-borne diseases.

Source: Irish Independent June 15, 2020 06:33 UTC